Article
The Hsp90 inhibitor SNX-7081 is synergistic with fludarabine nucleoside via DNA damage and repair mechanisms in human, p53-negative chronic lymphocytic leukemia.
Oncotarget - 1 Dec 2015
Kaufman Kimberley L, Jenkins Yiping, Alomari Munther, Mirzaei Mehdi, Best O Giles, Pascovici Dana, Mactier Swetlana, Mulligan Stephen P, Haynes Paul A, Christopherson Richard I
Abstract excerpt
Clinical trials of heat shock protein 90 (Hsp90) inhibitors have been limited by high toxicity. We previously showed that the Hsp90 inhibitor, SNX-7081, synergizes with and restores sensitivity to fludarabine nucleoside (2-FaraA) in human chronic lymphocytic leukemia (CLL) cells with lesions in the p53 pathway (Best OG, et al., Leukemia Lymphoma 53:1367-75, 2012). Here, we used label-free quantitative shotgun...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.